La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Dermapharm Holding Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Hans-Georg Feldmeier

Amministratore delegato

€1.4m

Compenso totale

Percentuale dello stipendio del CEO	59.7%
Mandato del CEO	7.1yrs
Proprietà del CEO	n/a
Durata media del management	2yrs
Durata media del Consiglio di amministrazione	7.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Hans-Georg Feldmeier rispetto agli utili di Dermapharm Holding?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	€83m
Mar 31 2024	n/a	n/a	€57m
Dec 31 2023	€1m	€821k	€62m
Sep 30 2023	n/a	n/a	€95m
Jun 30 2023	n/a	n/a	€123m
Mar 31 2023	n/a	n/a	€146m
Dec 31 2022	€1m	€800k	€134m
Sep 30 2022	n/a	n/a	€176m
Jun 30 2022	n/a	n/a	€185m
Mar 31 2022	n/a	n/a	€211m
Dec 31 2021	€1m	€800k	€210m
Sep 30 2021	n/a	n/a	€162m
Jun 30 2021	n/a	n/a	€123m
Mar 31 2021	n/a	n/a	€95m
Dec 31 2020	€736k	€411k	€86m

Compensazione vs Mercato: La retribuzione totale di Hans-Georg ($USD 1.54M ) è inferiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 2.24M ).

Compensazione vs guadagni: La retribuzione di Hans-Georg è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Hans-Georg Feldmeier

7.1yrs

Mandato

€1,375,000

Compensazione

Dr. Hans-Georg Feldmeier is the Chief Executive Officer and Chairman of the Management Board at Dermapharm Holding SE and also serves as Member of the Management Board from August 2017.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Hans-Georg Feldmeier	CEO & Chairman of the Management Board	7.1yrs	€1.38m	Nessun dato
Christof Dreibholz	CFO, Chief Compliance Officer & Member of Management Board	1.8yrs	€617.00k	Nessun dato
Andreas Eberhorn	Chief Marketing Officer & Member of Management Board	2yrs	€612.00k	Nessun dato
Britta Hamberger	Head of Investor Relations & Corporate Communications	no data	Nessun dato	Nessun dato

2.0yrs

Durata media

Gestione esperta: Il team dirigenziale di 0A5J è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Lothar Lanz	Independent Member of Supervisory Board	6.7yrs	€80.00k	Nessun dato
Wilhelm Beier	Chairman of the Supervisory Board	7.1yrs	€80.00k	Nessun dato
Erwin Kern	Independent Vice Chairman of the Supervisory Board	7.1yrs	€80.00k	Nessun dato

7.1yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0A5J sono considerati esperti (durata media dell'incarico 7 anni).

Dermapharm Holding Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024

Dermapharm Holding SE Announces Executive Changes

Recent updates

Second quarter 2024 earnings released: EPS: €0.32 (vs €0.17 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.81 (vs €0.92 in 1Q 2023)

Dermapharm Holding SE to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings released: EPS: €1.16 (vs €2.49 in FY 2022)

Dermapharm Holding SE, Annual General Meeting, Jun 27, 2024

Dividend of €0.88 announced

Dermapharm Holding SE to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial position

Third quarter 2023 earnings released: EPS: €0.46 (vs €0.98 in 3Q 2022)

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.27 profit in 2Q 2022)

Upcoming dividend of €1.05 per share at 2.3% yield

Full year 2022 earnings released: EPS: €2.49 (vs €3.89 in FY 2021)

Third quarter 2022 earnings released: EPS: €0.98 (vs €1.15 in 3Q 2021)

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: €0.27 (vs €0.74 in 2Q 2021)

Dermapharm Holding SE Announces Executive Changes

Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022

Upcoming dividend of €2.17 per share

First quarter 2022 earnings released: EPS: €0.69 (vs €0.67 in 1Q 2021)

Dermapharm Holding SE Provides Earnings Guidance for the Full Year 2022

Full year 2021 earnings released: EPS: €3.89 (vs €1.59 in FY 2020)

Dermapharm Holding SE Proposes Dividend for the Year 2021

Investor sentiment deteriorated over the past week

Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED).

Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED).

Dermapharm Holding SE (XTRA:DMP) entered into an agreement to acquire C3 - Cannabionoid Compound Company GmbH from Canopy Growth Corporation (TSX:WEED) for approximately €120 million.

Third quarter 2021 earnings released: EPS €1.15 (vs €0.42 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.74 (vs €0.22 in 2Q 2020)

First quarter 2021 earnings released: EPS €0.67 (vs €0.50 in 1Q 2020)

Dermapharm Confirms Earnings Guidance for 2021

Full year 2020 earnings released: EPS €1.59 (vs €1.43 in FY 2019)

Dermapharm Holding SE Provides Revenue Guidance for Fiscal 2021

Investor sentiment improved over the past week

Dermapharm Holding SE Expects the Collaboration with BioNTech SE for the Production of the Covid-19 Vaccine Comirnaty

New 90-day high: €63.75

New 90-day high: €58.25

Market bids up stock over the past week

Revenue misses expectations

Third quarter 2020 earnings released: EPS €0.42

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media